Metabolic clearance rates (MCR) of arginine vasopressin (AVP) were measured serially in five women starting before conception, during gestational weeks 7-8 (early), 22-24 (middle), and 36-38 (late pregnancy), and again 10-12 wk postpartum. Hormonal disposal rates were determined after water loading to suppress endogenous AVP release using a constant infusion method designed to achieve three different steadystate concentrations of plasma AVP (PAvp) on each test occasion. Dose schedules were altered in mid-and late pregnancy to obtain comparable AVP levels at each stage of the protocol. Prehydration decreased plasma osmolality sufficiently to suppress AVP release, as circulating AVP-neurophysin measured serially in three of the women was undetectable. ( 1-3) . Another interesting osmoregulatory change is that the rise in circulating AVP levels provoked by increases in body tonicity (APAVP/APmO1), unaltered early in gestation, is markedly decreased in the third trimester (3). This latter event could represent a reduced secretory response to osmotic stimuli, but might also reflect an increase in hormonal metabolic clearance rates (MCR). Indeed, in a preliminary report we have noted that the MCR are increased fourfold during the third trimester compared with measurements postpartum (4). The present study extends this latter observation. MCR of AVP were measured serially in volunteers, starting before conception, continuing throughout pregnancy, and again 10-12 wk postpartum. This study was designed to determine hormonal disposal rates at three different steady-state plasma concentrations during each test. Furthermore, by manipulating exogenous AVP infusion rates we succeeded in duplicating these levels and were able to compare their influence both on the MCR and urine osmolality (Uosmoi) first before, three times during, and again after pregnancy. Results were also correlated with circulating levels of cystineaminopeptidase (EC 3.4.11.3; vasopressinase), an enzyme recently implicated in the etiology of transient vasopressin-resistant diabetes insipidus (DI) of pregnancy (5).
thresholds for thirst and arginine vasopressin (AVP) release decrease -10 mosmol/kg during the first trimester. These decrements are maintained till term (1) (2) (3) . Another interesting osmoregulatory change is that the rise in circulating AVP levels provoked by increases in body tonicity (APAVP/APmO1), unaltered early in gestation, is markedly decreased in the third trimester (3) . This latter event could represent a reduced secretory response to osmotic stimuli, but might also reflect an increase in hormonal metabolic clearance rates (MCR). Indeed, in a preliminary report we have noted that the MCR are increased fourfold during the third trimester compared with measurements postpartum (4) . The present study extends this latter observation. MCR of AVP were measured serially in volunteers, starting before conception, continuing throughout pregnancy, and again 10-12 wk postpartum. This study was designed to determine hormonal disposal rates at three different steady-state plasma concentrations during each test. Furthermore, by manipulating exogenous AVP infusion rates we succeeded in duplicating these levels and were able to compare their influence both on the MCR and urine osmolality (Uosmoi) first before, three times during, and again after pregnancy. Results were also correlated with circulating levels of cystineaminopeptidase (EC 3.4.11.3; vasopressinase), an enzyme recently implicated in the etiology of transient vasopressin-resistant diabetes insipidus (DI) of pregnancy (5) .
Methods

Subjects
Serial studies were performed on five normotensive healthy subjects once before conception, between gestational weeks 7 and 8, 22 and 24, 36 and 38 (designated as early, mid-, and late pregnancy), and again 10-12 wk postpartum, when none were breast feeding or ingesting oral contraceptives. In addition, two women with a single kidney, one subject carrying twins and another triplets, were studied but only in late pregnancy and postpartum. All [3] ), but these changes were not significant. Similarly, the MCR in late gestation were slightly higher than those in mid-pregnancy, but again these increments did not reach significance. In essence, the greatest changes took place between gestational weeks 6 and 8 and 22 and 24.
Note also that the MCR at any stage was unaltered despite virtually tripling circulating hormone concentrations between the first and final infusion rates of each test. (8, 9) and became undetectable (< 0.5 ng/ml) after hydration.
The MCR in the women with a single kidney and those carrying twins and triplets are summarized in Table III. These   1314 Davison', Sheills, Barron, Robinson, and Lindheimer Fig. 3 compares vasopressinase activity derived by our isotope index and a standard substrate method. Activity was detected earlier in pregnancy using the tracer method (7-8 wk) and then the substrate technique (9-10 wk). Enzyme activity increased 40-fold by mid-and 50-fold by late pregnancy using either assay (P < 0.00 1), while vasopressinase remained detectable for a longer period after gestation using the tracer (5-6 wk) compared with the substrate (4 wk) assay. Not shown on the figure, enzyme levels in the women carrying twins and triplets were consistently at the upper 1 SD boundary, their final values near term being 270 and 281 mIU/ml, respectively.
Discussion
We monitored clearances of exogenously infused AVP in five women starting before conception, continuing throughout pregnancy, and 8-10 wk postpartum. The MCR at mid-and late pregnancy was markedly increased compared with values in the first trimester as well as when the women were not pregnant. Hormonal disposal rates at any phase of the study were uninfluenced by the circulating levels of AVP and the increments observed during mid-and late gestation seemed to correlate with striking increases in vasopressinase activity present at these times. We also measured basal AVP in these subjects, noting that levels were similar throughout pregnancy as well as the nonpregnant state. Thus, hormonal production rates must also have increased by mid-gestation.
The observation that infused AVP is cleared more rapidly during gestation confirms and extends a recent report in which we suggested that the MCR ofendogenously secreted hormone was increased in late pregnancy (12) . This was based on observations during and after pregnancy in a protocol where PAVP had been increased secondarily to increments in Posmol induced by hypertonic saline infusion after which the subjects drank water, a maneuver that rapidly suppresses endogenous hormone release by an oropharyngeal-neuroendocrine reflex, even in the face of sustained hyperosmolality (12) . Within minutes of drinking, AVP levels started to decrease and the hormonal t1/2 in late gestation was half that in early pregnancy or postpartum. However, as noted in that report, peak AVP levels attained with hypertonic saline were too low (usually between 5 and 10 pg/ml), and post-drinking blood samples with detectable PAVP too few, to accurately assess the t/2. Nevertheless, these previous observations add confidence to the conclusion that our present infusion clearance data reflect the MCR of endogenously secreted hormone. This is not a moot (13) . Also, the percent rise in MCR noted in the two gravidas with single kidneys was similar to that in the normal volunteers. The placenta, the mass of which increases throughout gestation, may inactivate substantial quantities of AVP in situ. In preliminary studies we perfused 25I-AVP at rates comparable to in vivo conditions (14) . The preparation perfused on the maternal side was capable of inactivating -1 ng/min of tracer, while perfusion of the fetal side was without effect. Thus, the placenta too may account for the increased MCR observed on these studies. Of interest, also, is that estimated trophoblastic mass increases 1,000-fold between gestational weeks 6 and 24, plateauing thereafter (15) . Uteroplacental blood flow follows a similar pattern of change, and at term has been estimated to be about 500 ml/min blood flow (16) . In these respects the MCR ofAVP was almost maximal by [22] [23] [24] wk, increasing slightly but not significantly near term. The placenta is also the source of circulating vasopressinase, an enzyme capable of inactivating large quantities ofAVP in vitro. Whether or not this enzyme is active in vivo, however, is unclear, but it is of interest that alterations in the hormonal MCR correlated best with increments in plasma vasopressinase in the present study. Of further interest, pregnant sheep, whose placentae produce no detectable vasopressinase, do not have an increased MCR of AVP during their gestation (17) . Currently we are measuring the MCR of l-desamino-[8-D-arginine]vasopressin (DDAVP), an AVP analogue resistant to enzymatic inactivation by cystine-aminopeptidase (18). If vasopressinase does play a role in the increased MCR of AVP during mid-and late gestation, any increments in the disposal rate of infused DDAVP ought to be considerably less than those observed for the native hormone.
Oxytocin, which differs from AVP by just two amino acids, is also inactivated in vitro by cystine-aminopeptidase, and thus might be expected to be metabolized in a manner similar to vasopressin in pregnant women. Surprisingly, however, Amico et al. observed no differences in the MCR of infused oxytocin into term pregnant subjects compared with nonpregnant vol- unteers (19) . However, there is evidence that oxytocin may be more resistant to enzymatic degradation in vivo, especially in the central nervous system (20) . Also, and in contrast with observations reported by Amico et al. (19), we have preliminary data that suggest that the MCR of infused oxytocin is increased in a manner similar to that of AVP at term (21) . The increased MCR of AVP in pregnancy may explain certain other changes in osmoregulation during gestation. As noted previously, the rise in circulating hormone provoked by increasing body tonicity (APAvp/APosmo) decreases in the third trimester. Initially we considered that this might reflect a reduced secretory response to osmotic stimuli, as occurs in certain hypervolemic states such as primary aldosteronism (22), for indeed extracellular volume increases markedly in pregnancy (23). However, the osmotic sensitivity to thirst (Athirst intensity/APOSmOj; see reference 3) would also be expected to be decreased in such circumstances (24) and it was not (3). Another possibility considered was that an increase in hormonal disposal rate would explain reductions in the ratio APAVP/APosmol with little influence on the relationship between thirst intensity and Posmoi. This led to the current study and data supporting the latter hypothesis.
Several problems in water handling known to occur in pregnancy may also relate to our observations. For example, some women with central DI may require more AVP during gestation. There is a syndrome labeled transient DI of pregnancy that usually presents during the second half ofgestation and remits postpartum (25) . Some of the women with this complication may have subclinical lesions of central DI brought to the fore by the increased hormonal MCR of pregnancy (25) (26) (27) . Still other patients have been described with transient vasopressin-resistant DI and high circulating levels of vasopressinase, and one of them described by Durr et al. (5) responded to DDAVP after large doses of AVP had failed to effect UOsmoi.
Performance of a serial study also allowed us to evaluate the influence of pregnancy on renal effects of AVP. Some have suggested resistance to the hydroosmotic effects of AVP upon the kidney during gestation, both in humans and in two animal species (28) (29) (30) (31) . Several reasons, including increments during pregnancy in PGE2 excretion, a hormone that opposes the effects of AVP at the tubular level, have been offered to explain this resistance. Review of the literature, however, reveals that such claims have been based solely on the influence of exogenously administered hormone on Uosmol, without noting if such maneuvers achieve similar PAvp levels during the pregnant and nonpregnant states. For example, administration of similar quantities of AVP during the nongravid and pregnant states would be expected to produce lower PAVP values in the latter ifeither the MCR or volume ofdistribution were increased in pregnant and control subjects or animals.
Our experiments permitted comparison of Uomol at similar AVP levels, measured during steady-state conditions. Similar levels of PAVP produced approximately the same UOSmoi in early, mid-, and late gestation as well as in the nonpregnant state (Table I and Fig. 2) .
Finally, our observations in postpartum subjects are consistent with the MCR for AVP measured in nonpregnant populations and reported by Robertson et al. (32) , Beardwell et al. (33) , and Moses and Steciak (34) , who used constant-infusion techniques, and Engel et al. (35) , who performed a single-injection protocol. Moses and Steciak, however, observed increments in the MCR as PAvp increased, but we did not. This discrepancy may be explained by the fact that we measured PAVP at three levels within the physiological range, while even the lowest concentrations observed by Moses and Steciak (34) were supraphysiological.
In conclusion, these data demonstrate that the MCR of AVP similar to nonpregnant values during gestational weeks 7-8 measures fourfold by weeks 22-24 and remains at these elevated levels through term. These rises seem to parallel the periods of rapid increase in both trophoblastic mass and circulating vasopressinase. The increase in hormonal disposal rates may explain the appearance of certain polyuric syndromes in late gestation.
